{"id":"NCT02165215","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors","officialTitle":"Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-12","primaryCompletion":"2020-04-06","completion":"2020-04-06","firstPosted":"2014-06-17","resultsPosted":"2021-06-15","lastUpdate":"2021-08-19"},"enrollment":359,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"DRUG","name":"Etrolizumab","otherNames":["RG7413","RO5490261","PRO145223","rhuMAb Beta7"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Open-Label Induction Phase: Etrolizumab","type":"EXPERIMENTAL"},{"label":"Double-Blind Maintenance Phase: Etrolizumab","type":"EXPERIMENTAL"},{"label":"Double-Blind Maintenance Phase: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely active UC who are naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.","primaryOutcome":{"measure":"Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)","timeFrame":"Week 62","effectByArm":[{"arm":"Double-Blind Maintenance Phase: Etrolizumab","deltaMin":29.6,"sd":null},{"arm":"Double-Blind Maintenance Phase: Placebo","deltaMin":20.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1942"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":13},"locations":{"siteCount":104,"countries":["United States","Brazil","Canada","Czechia","Denmark","Germany","Hungary","India","Israel","Italy","Mexico","Poland","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":["34798037","32445184"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":358},"commonTop":["Colitis ulcerative","Nasopharyngitis","Arthralgia","Diarrhoea","Abdominal pain"]}}